Aldeyra Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Aldeyra Therapeutics has a total shareholder equity of $119.8M and total debt of $15.1M, which brings its debt-to-equity ratio to 12.6%. Its total assets and total liabilities are $148.3M and $28.5M respectively.
Key information
12.6%
Debt to equity ratio
US$15.15m
Debt
Interest coverage ratio | n/a |
Cash | US$142.82m |
Equity | US$119.80m |
Total liabilities | US$28.53m |
Total assets | US$148.33m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 137's short term assets ($147.8M) exceed its short term liabilities ($22.3M).
Long Term Liabilities: 137's short term assets ($147.8M) exceed its long term liabilities ($6.3M).
Debt to Equity History and Analysis
Debt Level: 137 has more cash than its total debt.
Reducing Debt: 137's debt to equity ratio has increased from 0% to 12.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 137 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 137 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 9.2% each year